CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...

MONTREAL, April 17, 2026 /CNW/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY (R) injection (gadopiclenol), a macrocyclic gadolinium-based ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of ...

The US Food and Drug Administration (FDA) has granted expanded clearance to Bayer’s Medrad MRXperion, broadening the magnetic resonance (MR) injection system’s application across a wider range of MRI ...

Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 No significant financial relationships to disclose. This is ...

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that its MEDRAD ® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the ...

When you get a magnetic resonance imaging (MRI) scan, you might get an injection of a contrast fluid called gadolinium, a kind of “dye” that highlights your organs, blood vessels, and tissues to ...

Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...

Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY® injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent (GBCA), for use in ...

Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...